Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Forced To Update Approved Products List In Do-Not-Compound Review

Executive Summary

ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.

You may also be interested in...

Opioid Compounding Restrictions Could Create New Headaches For FDA

Advisory committee votes to add oxycodone to do-not-compound list, but will compounders now begin producing abuse-deterrent formulations?

Pharmacy Compounding Advisory Committee Votes Mostly In Unison

In first meeting after multi-year absence, FDA’s Pharmacy Compounding Advisory Committee takes 33 votes on do-not-compound and bulk substances lists.

FDA Field Operations Would Endure Reductions Under Budget

President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts